Biotech company Enzene Biosciences (Enzene), a subsidiary of Alkem Laboratories, has raised $50 million from Alkem Laboratories, Eight Roads Ventures, and F-Prime Capital.
This includes direct costs, such as medical treatments and medications, as well as indirect costs related to lost productivity and decreased quality of life. It’s
Ambien Cheap a delicate balance between managing symptoms and maintaining a good quality of life. For
Get Online Xanax Prescription instance, engaging in regular physical activity can help regulate hormones and improve mood, which may in turn alleviate some symptoms associated with cervical dystonia. The comprehensive care for such individuals must involve a multidisciplinary team that addresses
Ambien Overnight Shipping both the eating disorder and its physical manifestations, including the cognitive impairments that may arise
Ambien Without Prescription from repeated vomiting episodes. Thus, the journey continues, as the evolution of clinical practice unfolds in the context of both science and the human experience. In this context, managing nutrition becomes crucial, as a balanced diet can impact overall
Buy Tramadol 100 Mg Online health and weight stability. As awareness of these
Prednisone Cheap issues grows, so does the call for public health measures
Soma Discount aimed at improving air quality, which could subsequently benefit both respiratory health and cognitive clarity for the population as a whole. Many organizations in the United States now offer resources specifically tailored to individuals with asthma and concurrent mental health issues. Moreover, recent conversations around mental health in schools and workplaces have led to
Ambien 10 Mg Price the implementation of wellness programs that prioritize mental
Buy Valium 10 Mg Online health education.
The company plans to use the raised capital to improve manufacturing capabilities and drive expansion in India and the US.
“We are thrilled to be partnering with Alkem Laboratories and Enzene to build a global biosimilars and biologics powerhouse out of India,” said Dr Prem Pavoor, Senior Partner, Head of India & Healthcare Investments, Eight Roads Ventures.
According to a statement, Enzene, based in Pune, has established fully integrated biotech process development and manufacturing capabilities across numerous modalities and platforms. It has developed a captive pipeline of biosimilars that have been distributed through out-licensing agreements to pharmaceutical firms operating on a global scale. Additionally, it offers biotechnology companies with full-range contract development and manufacturing services.
Enzene provides various biologics services, including the capability to develop clones and implement good manufacturing practices (GMP), all supported by bioreactors with capacities ranging from 20 to 2,000 litres. Biosimilars, new biologics, synthetic peptides, and phytopharmaceuticals are its main product categories.
Enzene Biosciences Ltd. CEO Dr Himanshu Gadgil hoped to continue on the company’s mission to deliver innovative and affordable biomanufacturing for novel biologics and biosimilars globally.
Source @Indianstartupnews
